Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Differential regulation of fibroblast growth factor receptor 1 trafficking and function by extracellular galectins.

Kucińska M, Porębska N, Lampart A, Latko M, Knapik A, Zakrzewska M, Otlewski J, Opaliński Ł.

Cell Commun Signal. 2019 Jun 17;17(1):65. doi: 10.1186/s12964-019-0371-1.

2.

Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins.

Latko M, Czyrek A, Porębska N, Kucińska M, Otlewski J, Zakrzewska M, Opaliński Ł.

Cells. 2019 May 14;8(5). pii: E455. doi: 10.3390/cells8050455. Review.

3.

Crosstalk between p38 and Erk 1/2 in Downregulation of FGF1-Induced Signaling.

Zakrzewska M, Opalinski L, Haugsten EM, Otlewski J, Wiedlocha A.

Int J Mol Sci. 2019 Apr 12;20(8). pii: E1826. doi: 10.3390/ijms20081826.

4.

Identification of a peptide antagonist of the FGF1-FGFR1 signaling axis by phage display selection.

Lipok M, Szlachcic A, Kindela K, Czyrek A, Otlewski J.

FEBS Open Bio. 2019 May;9(5):914-924. doi: 10.1002/2211-5463.12618. Epub 2019 Apr 9.

5.

Targeting Cellular Trafficking of Fibroblast Growth Factor Receptors as a Strategy for Selective Cancer Treatment.

Porębska N, Latko M, Kucińska M, Zakrzewska M, Otlewski J, Opaliński Ł.

J Clin Med. 2018 Dec 20;8(1). pii: E7. doi: 10.3390/jcm8010007. Review.

6.

Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401.

Serwotka-Suszczak AM, Sochaj-Gregorczyk AM, Pieczykolan J, Krowarsch D, Jelen F, Otlewski J.

Int J Mol Sci. 2018 Nov 20;19(11). pii: E3676. doi: 10.3390/ijms19113676.

7.

Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity.

Chudzian J, Szlachcic A, Zakrzewska M, Czub M, Pustula M, Holak TA, Otlewski J.

Int J Mol Sci. 2018 Aug 21;19(9). pii: E2470. doi: 10.3390/ijms19092470.

8.

Translocation of Exogenous FGF1 and FGF2 Protects the Cell against Apoptosis Independently of Receptor Activation.

Kostas M, Lampart A, Bober J, Wiedlocha A, Tomala J, Krowarsch D, Otlewski J, Zakrzewska M.

J Mol Biol. 2018 Oct 19;430(21):4087-4101. doi: 10.1016/j.jmb.2018.08.004. Epub 2018 Aug 9.

9.

FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1.

Świderska KW, Szlachcic A, Opaliński Ł, Zakrzewska M, Otlewski J.

Int J Mol Sci. 2018 Jul 19;19(7). pii: E2098. doi: 10.3390/ijms19072098.

10.

Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors.

Krzyscik MA, Zakrzewska M, Sørensen V, Sokolowska-Wedzina A, Lobocki M, Swiderska KW, Krowarsch D, Wiedlocha A, Otlewski J.

ACS Omega. 2017 Jul 31;2(7):3792-3805. doi: 10.1021/acsomega.7b00116. Epub 2017 Jul 21.

11.

High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1.

Opaliński Ł, Szymczyk J, Szczepara M, Kucińska M, Krowarsch D, Zakrzewska M, Otlewski J.

Int J Mol Sci. 2018 May 10;19(5). pii: E1435. doi: 10.3390/ijms19051435.

12.

Generation of high-affinity, internalizing anti-FGFR2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers.

Borek A, Sokolowska-Wedzina A, Chodaczek G, Otlewski J.

PLoS One. 2018 Feb 8;13(2):e0192194. doi: 10.1371/journal.pone.0192194. eCollection 2018.

13.

Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1.

Sochaj-Gregorczyk AM, Ludzia P, Kozdrowska E, Jakimowicz P, Sokolowska-Wedzina A, Otlewski J.

Int J Mol Sci. 2017 Aug 3;18(8). pii: E1688. doi: 10.3390/ijms18081688.

14.

Antibody-induced dimerization of FGFR1 promotes receptor endocytosis independently of its kinase activity.

Opaliński Ł, Sokołowska-Wędzina A, Szczepara M, Zakrzewska M, Otlewski J.

Sci Rep. 2017 Aug 2;7(1):7121. doi: 10.1038/s41598-017-07479-z.

15.

The autoinhibitory function of D1 domain of FGFR1 goes beyond the inhibition of ligand binding.

Opalinski L, Szczepara M, Sokolowska-Wedzina A, Zakrzewska M, Otlewski J.

Int J Biochem Cell Biol. 2017 Aug;89:193-198. doi: 10.1016/j.biocel.2017.06.015. Epub 2017 Jun 23.

PMID:
28652212
16.

High-Yield Site-Specific Conjugation of Fibroblast Growth Factor 1 with Monomethylauristatin E via Cysteine Flanked by Basic Residues.

Lobocki M, Zakrzewska M, Szlachcic A, Krzyscik MA, Sokolowska-Wedzina A, Otlewski J.

Bioconjug Chem. 2017 Jul 19;28(7):1850-1858. doi: 10.1021/acs.bioconjchem.7b00158. Epub 2017 Jun 23.

PMID:
28598150
17.

High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer.

Sokolowska-Wedzina A, Chodaczek G, Chudzian J, Borek A, Zakrzewska M, Otlewski J.

Mol Cancer Res. 2017 Aug;15(8):1040-1050. doi: 10.1158/1541-7786.MCR-16-0136. Epub 2017 May 8.

18.

Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy.

Jurek PM, Zabłocki K, Waśko U, Mazurek MP, Otlewski J, Jeleń F.

Int J Nanomedicine. 2017 Apr 11;12:2941-2950. doi: 10.2147/IJN.S125231. eCollection 2017.

19.

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.

Serwotka-Suszczak AM, Sochaj-Gregorczyk AM, Pieczykolan J, Krowarsch D, Jelen F, Otlewski J.

Int J Mol Sci. 2017 Feb 14;18(2). pii: E401. doi: 10.3390/ijms18020401. Erratum in: Int J Mol Sci. 2018 Nov 20;19(11):.

20.

Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.

Szlachcic A, Zakrzewska M, Lobocki M, Jakimowicz P, Otlewski J.

Drug Des Devel Ther. 2016 Aug 9;10:2547-60. doi: 10.2147/DDDT.S105896. eCollection 2016.

Supplemental Content

Loading ...
Support Center